Alkermes Q1 Earnings Call Highlights

14 hours ago 2

MarketBeat

Tue, May 5, 2026 astatine 9:14 AM CDT 9 min read

Alkermes logo

Alkermes (NASDAQ:ALKS) executives highlighted a beardown commencement to 2026 and the completion of the Avadel Pharmaceuticals acquisition during the company’s first-quarter net call, pointing to accelerating standard crossed addiction and psychiatry brands and a caller foothold successful slumber medicine done LUMRYZ.

Avadel acquisition adds LUMRYZ and expands slumber medicine strategy

Management framed the mid-February adjacent of the Avadel acquisition arsenic a large strategical step. CEO Richard Pops said the woody is “a cardinal constituent of our strategy to go a person successful the slumber medicine space,” adding that LUMRYZ is “early successful its commercialized beingness and has important imaginable for growth.”

→ Roblox Stock Slides to New Low arsenic Safety Changes Weigh connected Outlook

Pops said the institution believes the acquisition strengthens Alkermes’ fiscal illustration portion besides giving it a commercialized beingness successful slumber medicine “well successful beforehand of the imaginable support and motorboat of alixorexton.” He said gathering relationships with slumber specialists and different stakeholders present could “accelerate our imaginable motorboat trajectory for alixorexton.”

Pops besides referenced “the announced introduction of Eli Lilly into this therapeutic space” adjacent the extremity of the quarter, describing it arsenic “external validation” for orexin-pathway therapies and noting what helium characterized arsenic constricted competitory entrants and scarce intelligence spot astir chemistry.

Product income rise; LUMRYZ contributes post-close

→ The Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It Launches

Chief Commercial Officer Todd Nichols said Alkermes present has commercialized capabilities successful 3 areas: addiction (VIVITROL), psychiatry (ARISTADA and LYBALVI), and slumber medicine (LUMRYZ). Nichols said integration of the Avadel commercialized squad is “progressing well,” with a combined squad “fully successful place” entering the 2nd quarter.

Net income from Alkermes’ proprietary merchandise portfolio accrued 38% year-over-year to $338.1 million, which Nichols said reflected coagulated demand, “certain favorable gross-to-net adjustments,” and six weeks of publication from LUMRYZ.

VIVITROL: Q1 nett income were $112.4 million. Nichols said show was driven by the company’s quality to capitalize connected “highly localized marketplace dynamics successful definite states and payer systems.” Full-year 2026 guidance was reiterated astatine $460 cardinal to $480 million.
ARISTADA family: Q1 nett income were $93.8 million, which Nichols said reflected “solid underlying demand.” Full-year guidance was reiterated astatine $365 cardinal to $385 million.
LYBALVI: Q1 nett income accrued 32% year-over-year to $92.4 million. Nichols said underlying full medicine (TRX) maturation was 21% year-over-year, driven by caller diligent starts and broader prescriber adoption. He said gross-to-net adjustments were astir 33% and are expected to widen into the “mid-30s” during the twelvemonth arsenic marketplace entree expands. Full-year guidance was reiterated astatine $380 cardinal to $400 million.